---
schema_version: "secwatch.filing_event.v1"
accession: "0001388658-26-000093"
form_type: "8-K"
ticker: "IRTC"
cik: "0001388658"
company_name: "iRhythm Holdings, Inc."
filed_at: "2026-11-05T21:15:28+00:00"
generated_at: "2026-11-05T21:16:09.796919+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# iRhythm Q3 revenue $221.6M, up 14.9% YoY; FY2026 revenue guidance raised to $890-895M

## Summary
- Revenue $221.6M vs $192.9M a year ago (+14.9%); gross margin 74.2%, up 310 bps, aided by ~$3.1M one-time tariff refund benefit.
- GAAP net loss $29.9M (-$0.90 per diluted share) vs $5.2M loss (-$0.16); adjusted net income $27.8M ($0.82/share) vs $0.06 loss per share.
- Adjusted EBITDA $51.2M at 23.1% margin, up $29.6M and 1,190 bps YoY; cash and marketable securities $560.7M as of September 30, 2026.
- FY2026 guidance: revenue $890-895M and adjusted EBITDA margin 15.5-16.0%, including ~$16M expected VitalConnect revenue from the Oct 5 close.
- VitalConnect acquisition closed October 5, 2026, adding an FDA-cleared mobile cardiac telemetry device; new $300M senior secured revolver closed November 3, 2026.

## SEC filing metadata
- accession: 0001388658-26-000093
- form_type: 8-K
- ticker: IRTC
- cik: 0001388658
- company_name: iRhythm Holdings, Inc.
- filed_at: 2026-11-05T21:15:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000093/0001388658-26-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000093/irtc-20261105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001388658-26-000093
- JSON: https://secwatch.observer/filing/0001388658-26-000093.json
- Plain text: https://secwatch.observer/filing/0001388658-26-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.